MC
Milenko Cicmil
Partner at Cure Ventures
Boston, Massachusetts
Overview
Milenko Cicmil is the Co-Founder and CEO of Tasca Therapeutics, a biotechnology company, and a Venture Partner at Cure Ventures. With a Ph.D. in biochemistry, he has held leadership roles at prominent organizations like Merck and Ipsen, focusing on drug discovery and development, and has a strong background in pharmacology and biotechnology.
Cicmil's career highlights include serving as Vice President at FogPharma, leading translational biology efforts, and as Vice President at Merck overseeing in vivo pharmacology for immuno-oncology and immunomodulation, showcasing his expertise in drug development and innovative research initiatives.
Work Experience
Visiting Research Fellow at Univ. of Reading, UK
2020 - Current
Partner
2021
Chairman Of The Board AMP Discovery
2021 - 2022
Vice President Global Head of external Innovation
2019 - 2021
Vice President - Translational Biology
2017 - 2019
Director at Merck Innovation Hub
2016 - 2017
Director Pharmacology Immuno-Oncology and Immunomodulation
2013 - 2016
Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.
Raised $5,586,000.00 from Private Capital Advisors.
Director In vivo Pharmacology R&I
2011 - 2013
Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.
Raised $5,586,000.00 from Private Capital Advisors.
Group Leader Integrative Pharmacology Discovery Bioscience - Inflammation
2007 - 2011
Senior Research Scientist
2004 - 2007
Senior Research Scientist
2002 - 2004
GE Healthcare provides a wide range of medical technologies and services to healthcare providers and researchers.
Raised $5,524,660,836.00 from Bill & Melinda Gates Foundation.
Translational Science - Research Fellow
2000 - 2002